With just-approved PARP inhibitor Zejula (niraparib) making its way in the marketplace, Tesaro Inc. has turned its phase I dose-escalating trial with anti-PD-1 antibody TSR-042 into a registration experiment in patients with metastatic, microsatellite instability (MSI)-high endometrial cancer who have progressed following one or two prior chemotherapy treatments.